Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemotherapy in Advanced NSCLC Previously Treated With PD-1/PD-L1 Inhibitor
NCT03083808Phase 2Completed
- Start
- Mar 2017
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC). Started Mar 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03083808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083808.